Ultragenyx Pharmaceutical Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the Annual Meeting of Stockholders held by Ultragenyx Pharmaceutical Inc. on June 9, 2016. The meeting was conducted virtually via the Internet. The record date for the meeting was April 12, 2016, with 39,009,156 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on four proposals. A total of 36,606,955 shares were voted in person or by proxy.
- Proposal 1 (Election of Directors): All three Class III nominees were elected to serve until the 2019 Annual Meeting.
- William Aliski: 34,818,905 votes For; 256,373 votes Against/Withheld.
- Lars Ekman, M.D., Ph.D.: 32,322,633 votes For; 2,752,645 votes Against/Withheld.
- Matthew K. Fust: 31,845,101 votes For; 3,230,177 votes Against/Withheld.
- Proposal 2 (Ratification of Accounting Firm): Stockholders ratified the selection of Ernst & Young LLP for the fiscal year ending December 31, 2016.
- Votes For: 36,561,279
- Votes Against: 44,653
- Abstentions: 1,023
- Proposal 3 (Say-on-Pay): Stockholders approved the advisory resolution regarding executive compensation.
- Votes For: 29,765,989
- Votes Against: 5,306,330
- Abstentions: 2,959
- Proposal 4 (Frequency of Say-on-Pay): Stockholders indicated a preference for annual Say-on-Pay voting.
- One Year: 32,932,540 votes
- Two Years: 455,076 votes
- Three Years: 1,675,548 votes
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The Board has approved holding future Say-on-Pay votes on an annual basis based on the results of Proposal 4.
Key Facts for Investor Verification
- Verify the full text of the Definitive Proxy Statement on Schedule 14A filed on April 18, 2016, for details on director nominees and executive compensation.
- Confirm the specific terms of the engagement with Ernst & Young LLP for the 2016 fiscal year.
- Review the company's subsequent filings for financial performance data, as this 8-K contains no financial metrics.
- Note that approximately 1.53 million broker non-votes were recorded for the director election and Say-on-Pay proposals.